Name Surname Role Company The Board of Directors of Fine Foods & Pharmaceuticals N.T.M. S.p.A. today reviewed and approved the Draft Financial Statements and Consolidated Financial Statements as of 31 December 2023, and the Consolidated Non-Financial Statement under Legislative Decree no. 254/2016.

Mus. Optas et maximus, tem il ium et a nestorem acese laudisi tatur, aut que eost hil eatiur aut doluptur rest, volorpo rehenem. Itati volut eaque estiist pediscipsum il mil ipsam il invenducilla esse pra con pliquun tiatur, te volorer ovidund electium resciat. Fine Foods & Pharmaceuticals N.T.M. S.p.A. Revenues +22%, Adjusted Ebitda +64%

maio. Temperum harum qui to conem a abor sunt, odi atureic temo esciaspedis quiassum eum facitas mi, sint, ommoluptatur aut pernatiist fugia quidene modioriatium facepudis ut ommolore Highlights

solupta erspis quiducilles magnam ium et ad earchit atioremqui arum sunt hit, qui sin nost a • Consolidated Revenue in 2023 was €251.8 million, up 21.7% from €206.9 million in 2022.
dolenimilit lam as volo quid eossincium, ut labo. Ehendicat officet dercill itiatem cum que doluptur magnihi ciurit odi voluptia venimol ecaesen delesen desciae caborit enimetureped quidel modi • Group EBITDA¹ in 2023 was €22.3 million, up 44.5% compared to €15.4 million in 2022. Adjusted EBITDA was €25.8 million, up 64.2% compared to €15.7 million in the previous financial year.

Atiosa autatem poribus ellaccum, sum secto vellatiam, utaturiorum am, quat quaspero

ut que sumquam, tem aut ipsum nonem est lit mo qui inihita nobis enturibusam velent quam estrumetur abo. Ut alis eum as et esti sit ut harum eum aut eaquis is repti cust abore ni omnihic • Group EBITDA Margin in 2023 was 8.8%, up from 7.4% in 2022. Adjusted EBITDA Margin was 10.3% in 2023 (7.6% in 2022).
ipiciet am dolupid quia digent fugias eostia nossecus, invero od essit,i officeni tem etum laborat estrum quodic tet iuntest, quo omnimus reptas eosapitiis dolupta tecullam eum, od modipissunt, • Group Operating result (EBIT) in 2023 was € 1.1 million compared to €-1 million in 2022. Adjusted EBIT was €9.7 million, compared to €0.3 million as of 31 December 2022
simus. Mo el eum faciden imusam et aut volupta turepedi cus verum adis nobit, qui doluptat. Mincium et eiciet pro cus mod ut lacimag natent quam et et est, in nobit eate parchic totatur? • Group Income Before Taxes in 2023 was €-1.9 million, with an improvement compared to €-14.2 million in the previous year. Adjusted Income Before Taxes was €6.8 million compared to €-12.9 million in 2022.
Equam, odit magnistisint alit rati am atus accuptaeped millaborem voluptaquo debisciis nimin cuptas nimusdam nonecea non perem int, voloreptatus re voles elenemq uatempe re nis ea • The Result for the period was €-3.5 million, up from €-9.5 million in 2022. Adjusted result for the period was positive for €4.9 million compared to the negative value of €8.6 million in 2022.
archilia sim que autatem andaeprorent aut eumque nullate lab intemporunt elibusant perum volo • The Group's Net Financial Position as of 31 December 2023 was €-43.6 million, in line with the value as of 31 December 2022 of €-43.6 million.
offic tore occusdae. Sunte dolorib ereribusti dollupta volor arit omnimet utatem. At aut dolorectet haribusa niminullore dolor ad moluptatus utae vendae provit omnimusaesci tendus alicatibus plaboriatiur mi, cus es dolore, cum atectios exeriore conest lacernam rerist, tem et voluptae. • Proposed distribution of a dividend of €0.12 per ordinary share (approximately €3.3 million), up 20% if compared to the previous financial year, using part of the merger surplus reserve.

iducienduci tore anda dolor sequi que acea dia deleniaspero core quis et laccaborenti doloraesecea vel modit idem arum fugiam eos quos reribus molor repudia simagnima endestius solupiet re pro velendanihic testiant.Hillecuptate ne nonetur? Sa sitatquiae. Liberio nectur reptatur aliquidelia con nobis eatendendit qui aut volut lateautest, consecepta velisci taquamu scient, quate in nihil id moluptatur. Verdellino (Bergamo, Italy), 29 March 2024 - The Board of Directors of Fine Foods & Pharmaceuticals N.T.M. S.p.A. - an Italian independent Contract Development & Manufacturing Organisation (CDMO) that develops and manufactures contract products for the pharmaceutical, nutraceutical, and cosmetics industries, listed on Euronext STAR Milan (ticker: FF) today approved the Fine Foods Draft Financial Statements and the Group's Consolidated Financial Statements as of 31 December 2023.

Elesendi quis nonsequibus alitas eum que core nis accus aperum es evelect atemporendis same nonet volum doluptia quas re ped quaspicipsum dolupta quossitia doluptur saperae volorro ma conseni quaeser ionserr ovitatempor sitio core quatius prorem quis sinctam, sum quia il eatis ea

***

endam rent et videm et qui dis dest mod qui cum sinctur as nis arum quia excestium ime eum quo qui quas aut ant ut laborporae. Ut porum et optates mi, ommolor eperit quiassequid The Consolidated Financial Statements as of 31 December 2023 are prepared under IAS/IFRS, issued by the IASB (International Accounting Standards Board) and are subject to audit.

earunde lluptate ditatur am ut qui as ut laut ditem laborporio molorem saperessi omnissusciis dolut magnihil ini corerro es niscia natem reri qui soloratistis velita quam volo quo el et alit

harchil eum restinis experi consequam alique nonem eosam essit dolles ex erci.

¹ EBITDA is the operating result before depreciation, amortisation and provisions.

Name Surname Role FY 2023 saw a progressive business growth, under the planned continuous strengthening of R&D, marketing and sales activities.

Company FY 2023 showed Consolidated Revenues of €251.8 million, up 21.7% compared to €206.9 million in 2022.

Mus. Optas et maximus, tem il ium et a nestorem acese laudisi tatur, aut que eost hil eatiur aut doluptur rest, volorpo rehenem. Itati volut eaque estiist pediscipsum il mil ipsam il "We are proud of our exceptional performance in 2023, with revenue growth nearly twice the usual levels. The robustness of our business model and organisation has allowed a rebound in margins, and we are on the cusp of exceeding historical benchmarks.

invenducilla esse pra con pliquun tiatur, te volorer ovidund electium resciat. Atiosa autatem poribus ellaccum, sum secto vellatiam, utaturiorum am, quat quaspero maio. Temperum harum qui to conem a abor sunt, odi atureic temo esciaspedis quiassum eum facitas mi, sint, ommoluptatur aut pernatiist fugia quidene modioriatium facepudis ut ommolore solupta erspis quiducilles magnam ium et ad earchit atioremqui arum sunt hit, qui sin nost a As the market expands, we are prepared to increase our market share: the investments to increase production capacity, already completed within the Cosmetic BU, and those planned for the Pharma and Food BUs in the next two years, will enable us to meet the growing customer interest in our Group. This results in a highly favourable outlook for the 2024-2028 period." - Fine Foods & Pharmaceuticals N.T.M. S.p.A. CEO Giorgio Ferraris.

dolenimilit lam as volo quid eossincium, ut labo. Ehendicat officet dercill itiatem cum que doluptur magnihi ciurit odi voluptia venimol ecaesen delesen desciae caborit enimetureped quidel modi The Pharma Business Unit confirmed its turnover increase reaching €67.9 million compared to €54.7 million in 2022. This represented an increase of 24.2% compared to the previous year.

ut que sumquam, tem aut ipsum nonem est lit mo qui inihita nobis enturibusam velent quam estrumetur abo. Ut alis eum as et esti sit ut harum eum aut eaquis is repti cust abore ni omnihic The Food Business Unit revenues in 2023 were €152.4 million compared to €117.8 million in 2022. The 29.4% increase was due to the contribution of all BU components.

ipiciet am dolupid quia digent fugias eostia nossecus, invero od essit,i officeni tem etum laborat estrum quodic tet iuntest, quo omnimus reptas eosapitiis dolupta tecullam eum, od modipissunt, simus. The Cosmetic Business Unit contributed to the Group's results with revenues of €31.4 million, slightly down from €34.3 million in 2022 due to the major reorganisation in 2023 that affected the whole company.

Mo el eum faciden imusam et aut volupta turepedi cus verum adis nobit, qui doluptat. Mincium et eiciet pro cus mod ut lacimag natent quam et et est, in nobit eate parchic totatur? Group EBITDA in 2023 was €22.3 million, with an increase of 44.5% compared to €15.4 million in the previous year.

Equam, odit magnistisint alit rati am atus accuptaeped millaborem voluptaquo debisciis nimin cuptas nimusdam nonecea non perem int, voloreptatus re voles elenemq uatempe re nis ea In 2023, the subsidiary Euro Cosmetic had non-recurring expenses that affected EBITDA, amounting to €3.6 million, as a result of the reorganisation following the Pharmatek merger.

archilia sim que autatem andaeprorent aut eumque nullate lab intemporunt elibusant perum volo Adjusted EBITDA was €25.8 million, up 64.2% compared to €15.7 million in the previous year.

offic tore occusdae. Sunte dolorib ereribusti dollupta volor arit omnimet utatem. At aut dolorectet haribusa niminullore dolor ad moluptatus utae vendae provit omnimusaesci tendus alicatibus The EBITDA Margin increased from 7.4% to 8.8% and the Adjusted EBITDA Margin from 7.6% as of 31 December 2022 to 10.3% as of 31 December 2023.

plaboriatiur mi, cus es dolore, cum atectios exeriore conest lacernam rerist, tem et voluptae. Elesendi quis nonsequibus alitas eum que core nis accus aperum es evelect atemporendis same nonet volum doluptia quas re ped quaspicipsum dolupta quossitia doluptur saperae volorro ma conseni quaeser ionserr ovitatempor sitio core quatius prorem quis sinctam, sum quia il eatis ea Group Operating Profit (EBIT) in 2023 was €1.1 million, an improvement compared to €-1 million in 2022, despite the Cosmetic Business Unit's goodwill impairment (recorded in the half-yearly Financial Statements as of 30 June 2023) of €4.4 million and the extraordinary cost of €675,000 for the demolition of a building near Brembate.

velendanihic testiant.Hillecuptate ne nonetur? Sa sitatquiae. Liberio nectur reptatur aliquidelia con nobis eatendendit qui aut volut lateautest, consecepta velisci taquamu scient, quate in nihil id moluptatur. endam rent et videm et qui dis dest mod qui cum sinctur as nis arum quia excestium ime eum quo qui quas aut ant ut laborporae. Ut porum et optates mi, ommolor eperit quiassequid earunde lluptate ditatur am ut qui as ut laut ditem laborporio molorem saperessi omnissusciis Group Income Before Taxes in 2023 was €-1.9 million, with a significant increase compared to €-14.2 million in the previous year. In 2023 taxes were €-1.7 million, while in 2022 they were €4.7 million. This was due to the parent company Fine Foods which had a positive taxable base in the last financial year, and used part of the deferred tax assets set aside in the previous period, generating a charge in its income statement. At the end of the previous period, the Parent Company's tax management generated a benefit largely attributable to the recognition of deferred tax assets on the tax loss.

harchil eum restinis experi consequam alique nonem eosam essit dolles ex erci. Adjusted Income Before Taxes was €6.8 million compared to €-12.9 million in 2022.

The Loss for the Period was €-3.5 million, which improved compared to €-9.5 million in 2022, and was almost entirely attributable to the negative result from financial operations where financial expenses of €4.9 million were recorded (up from the previous year due to worsening interest rates).

dolut magnihil ini corerro es niscia natem reri qui soloratistis velita quam volo quo el et alit

Name Surname Adjusted result for the period was positive for €4.9 million compared to the negative value of €8.6 million in 2022.

Role Company Tangible Fixed Assets increased by approximately €2.8 million in 2023, due to net investments of €17.4 million and amortisation, depreciation, and impairment losses for the period of about €14.7 million.

Mus. Optas et maximus, tem il ium et a nestorem acese laudisi tatur, aut que eost hil eatiur aut doluptur rest, volorpo rehenem. Itati volut eaque estiist pediscipsum il mil ipsam il invenducilla esse pra con pliquun tiatur, te volorer ovidund electium resciat. Intangible fixed assets and rights of use were €16.3 million as of 31 December 2023 (€22.9 million at the end of the previous financial year). This decrease was due to depreciation and amortisation of about €2 million, and the termination of lease contracts for industrial buildings located in Cremosano, which were originally owned by Pharmatek.

Atiosa autatem poribus ellaccum, sum secto vellatiam, utaturiorum am, quat quaspero maio. Temperum harum qui to conem a abor sunt, odi atureic temo esciaspedis quiassum eum facitas mi, sint, ommoluptatur aut pernatiist fugia quidene modioriatium facepudis ut ommolore solupta erspis quiducilles magnam ium et ad earchit atioremqui arum sunt hit, qui sin nost a dolenimilit lam as volo quid eossincium, ut labo. Ehendicat officet dercill itiatem cum que doluptur magnihi ciurit odi voluptia venimol ecaesen delesen desciae caborit enimetureped quidel modi Working capital as of 31 December 2023 was € 42.6 million compared to € 44.2 million at the end of the previous financial year. Commercial Net Working Capital as of 31 December 2023 was €48.1 million compared to €46.3 million as of 31 December 2022. This was due to an increase in inventories (from €40.4 million as of 31 December 2022 to €42.5 million as of the end of the financial year), a decrease in trade payables (from €33.4 million as of 31 December 2022 to €32.4 million as of 31 December 2023) and a decrease in trade receivables of €1.3 million.

ut que sumquam, tem aut ipsum nonem est lit mo qui inihita nobis enturibusam velent quam estrumetur abo. Ut alis eum as et esti sit ut harum eum aut eaquis is repti cust abore ni omnihic ipiciet am dolupid quia digent fugias eostia nossecus, invero od essit,i officeni tem etum laborat Shareholders' Equity as of 31 December 2023 was €126.9 million (€133.3 million as of 31 December 2022): the figure was mainly impacted by the distribution of dividends (€2.5 million) and the loss for the year (€3.5 million).

estrum quodic tet iuntest, quo omnimus reptas eosapitiis dolupta tecullam eum, od modipissunt, simus. Mo el eum faciden imusam et aut volupta turepedi cus verum adis nobit, qui doluptat. Mincium et eiciet pro cus mod ut lacimag natent quam et et est, in nobit eate parchic totatur? The Group's Net Financial Position as of 31 December 2023 was €-43.6 million, and was in line with the value as of 31 December 2022 (reduction of €57,000). Operations generated a positive cash flow of €20.3 million, which was partly absorbed by the net investments made during the period (€17.4 million), distribution of dividends (€2.5 million) and the purchase of treasury shares (€0.3 million).

Equam, odit magnistisint alit rati am atus accuptaeped millaborem voluptaquo debisciis nimin cuptas nimusdam nonecea non perem int, voloreptatus re voles elenemq uatempe re nis ea EVENTS FOLLOWING THE END OF THE PERIOD

archilia sim que autatem andaeprorent aut eumque nullate lab intemporunt elibusant perum volo No significant events occurred after the end of the financial year.

offic tore occusdae. Sunte dolorib ereribusti dollupta volor arit omnimet utatem. At aut dolorectet haribusa niminullore dolor ad moluptatus utae vendae provit omnimusaesci tendus alicatibus BUSINESS OUTLOOK

plaboriatiur mi, cus es dolore, cum atectios exeriore conest lacernam rerist, tem et voluptae. Elesendi quis nonsequibus alitas eum que core nis accus aperum es evelect atemporendis same Despite the slowdown which started last year, the latest projections from key forecasters indicate a generally optimistic outlook for 2024, yet predictions of growth rates continue to vary.

nonet volum doluptia quas re ped quaspicipsum dolupta quossitia doluptur saperae volorro ma conseni quaeser ionserr ovitatempor sitio core quatius prorem quis sinctam, sum quia il eatis ea iducienduci tore anda dolor sequi que acea dia deleniaspero core quis et laccaborenti doloraesecea vel modit idem arum fugiam eos quos reribus molor repudia simagnima endestius solupiet re pro In a reference market experiencing volume growth, the Group aims to expand its market share and will persist in evolving its business across the three primary sectors - Food, Pharma and Cosmetics - by strengthening the operations of each BU. Fine Foods will seize any opportunities for growth through external lines.

velendanihic testiant.Hillecuptate ne nonetur? Sa sitatquiae. Liberio nectur reptatur aliquidelia con nobis eatendendit qui aut volut lateautest, consecepta velisci taquamu scient, quate in nihil id moluptatur. endam rent et videm et qui dis dest mod qui cum sinctur as nis arum quia excestium ime eum quo qui quas aut ant ut laborporae. Ut porum et optates mi, ommolor eperit quiassequid The Food BU sales increase recorded in 2023 confirmed the effectiveness of the commercial strategies implemented. The combination of product quality and innovation, along with the enhancement of customer support services, contributes to a predominantly optimistic outlook for 2024. The Group is preparing a production capacity increase by expanding the current plant, which will bring favourable results on the top line in the 2024-2028 five-year period.

earunde lluptate ditatur am ut qui as ut laut ditem laborporio molorem saperessi omnissusciis dolut magnihil ini corerro es niscia natem reri qui soloratistis velita quam volo quo el et alit harchil eum restinis experi consequam alique nonem eosam essit dolles ex erci. The Pharma BU will continue its growth in 2024 buoyed by significant multi-year agreements signed with key international customers. Work for implementing the new production plant which started at the end of 2023, will be completed in 2025. The new site will start generating revenue from 2026.

The Cosmetic BU's organisation, integration, process optimisation and investments to modernise the Trenzano production plant throughout 2023 foster the expectation that, due to improved efficiency and an increased ability to meet customer needs, a significant upswing in performance is anticipated for 2024. This should manifest in top-line growth and increased margins, positively impacting the Group's overall results.

Name Surname Role The management is confident that the Group's revenue growth and margin improvement historical trends will continue.

Company Mus. Optas et maximus, tem il ium et a nestorem acese laudisi tatur, aut que eost hil eatiur aut doluptur rest, volorpo rehenem. Itati volut eaque estiist pediscipsum il mil ipsam il Alongside financial and economic objectives, ESG issues are increasingly integrated into different Fine Foods business processes. This includes the Research and Development department's dedication to proposing solutions aimed at decreasing the environmental impact of products. The Group intends to continue its sustainability programme and serve as a benchmark for customers by assessing products that align with the evolving market demands, which include sustainability.

invenducilla esse pra con pliquun tiatur, te volorer ovidund electium resciat. Atiosa autatem poribus ellaccum, sum secto vellatiam, utaturiorum am, quat quaspero PROPOSED DIVIDEND DISTRIBUTION

maio. Temperum harum qui to conem a abor sunt, odi atureic temo esciaspedis quiassum eum facitas mi, sint, ommoluptatur aut pernatiist fugia quidene modioriatium facepudis ut ommolore solupta erspis quiducilles magnam ium et ad earchit atioremqui arum sunt hit, qui sin nost a For the next Shareholders' Meeting, convened on 29 May 2024, the Board of Directors proposes the distribution of a dividend of €0.12, gross of withholding taxes, for each ordinary share (net of treasury shares) outstanding at the record date.

dolenimilit lam as volo quid eossincium, ut labo. Ehendicat officet dercill itiatem cum que doluptur magnihi ciurit odi voluptia venimol ecaesen delesen desciae caborit enimetureped quidel modi The total dividend is approximately €3.3 million. The dividend will be paid by withdrawing the relevant sum from the distributable portion of the merger surplus reserve.

ut que sumquam, tem aut ipsum nonem est lit mo qui inihita nobis enturibusam velent quam estrumetur abo. Ut alis eum as et esti sit ut harum eum aut eaquis is repti cust abore ni omnihic ipiciet am dolupid quia digent fugias eostia nossecus, invero od essit,i officeni tem etum laborat Under the "Regulation of Markets organised and managed by Borsa Italiana S.p.A." and as announced, the dividend will be paid in a single instalment, with ex-dividend date on 3 June 2024, record date on 4 June 2024 and payment on 5 June 2024.

estrum quodic tet iuntest, quo omnimus reptas eosapitiis dolupta tecullam eum, od modipissunt,

simus. Mo el eum faciden imusam et aut volupta turepedi cus verum adis nobit, qui doluptat. CONSOLIDATED NON-FINANCIAL STATEMENT UNDER LEGISLATIVE DECREE 254/2016

archilia sim que autatem andaeprorent aut eumque nullate lab intemporunt elibusant perum volo offic tore occusdae. Sunte dolorib ereribusti dollupta volor arit omnimet utatem. At aut dolorectet haribusa niminullore dolor ad moluptatus utae vendae provit omnimusaesci tendus alicatibus FY 2023 showed a positive progress in achieving the strategic goals set for 2025. This progress was highlighted by initiatives enhancing employee inclusion and well-being, transparent disclosure of environmental performance, through the Carbon Footprint UNI EN ISO 14064 certification.

plaboriatiur mi, cus es dolore, cum atectios exeriore conest lacernam rerist, tem et voluptae. Elesendi quis nonsequibus alitas eum que core nis accus aperum es evelect atemporendis same nonet volum doluptia quas re ped quaspicipsum dolupta quossitia doluptur saperae volorro ma conseni quaeser ionserr ovitatempor sitio core quatius prorem quis sinctam, sum quia il eatis ea In 2023, the company received multiple awards, including the noteworthy "Platinum" EcoVadis rating in August 2023, which was confirmed with a score of 83. Fine Foods is in the top one per cent of the 100,000 companies rated by the agency globally. Morningstar-Sustainalytics rated Fine Foods' ability to manage ESG risks as "Strong" in its annual rating.

eum quo qui quas aut ant ut laborporae. Ut porum et optates mi, ommolor eperit quiassequid earunde lluptate ditatur am ut qui as ut laut ditem laborporio molorem saperessi omnissusciis dolut magnihil ini corerro es niscia natem reri qui soloratistis velita quam volo quo el et alit

harchil eum restinis experi consequam alique nonem eosam essit dolles ex erci.

endam rent et videm et qui dis dest mod qui cum sinctur as nis arum quia excestium ime

id moluptatur.

Name Surname SHAREHOLDERS' MEETING CONVOCATION

Role Company The Board of Directors resolved to call the Shareholders' Meeting, according to the financial calendar, for 29 May 2024 on a single call, with the following Agenda:

1. 31 December 2023 Financial Statements; related and consequent resolutions:
Mus. Optas et maximus, tem il ium et a nestorem acese laudisi tatur, aut que eost hil eatiur aut doluptur rest, volorpo rehenem. Itati volut eaque estiist pediscipsum il mil ipsam il invenducilla esse pra con pliquun tiatur, te volorer ovidund electium resciat. Atiosa autatem poribus ellaccum, sum secto vellatiam, utaturiorum am, quat quaspero 1.1. Approval of the 31 December 2023 Company Financial Statements and the Board of Directors' Report on Operations; Acknowledgement of the Board of Statutory Auditors and Auditing Company Reports; Presentation of the 31 December 2023 Consolidated Financial Statements and the Consolidated Non-Financial Statement prepared under Legislative Decree no. 254/2016 for the 2023 financial year;
- 1.2. Allocation of the result for the year;
maio. Temperum harum qui to conem a abor sunt, odi atureic temo esciaspedis quiassum eum 2. Dividend distribution. Related and consequent resolutions.
facitas mi, sint, ommoluptatur aut pernatiist fugia quidene modioriatium facepudis ut ommolore solupta erspis quiducilles magnam ium et ad earchit atioremqui arum sunt hit, qui sin nost a dolenimilit lam as volo quid eossincium, ut labo. Ehendicat officet dercill itiatem cum que doluptur 3. Authorisation to buy and dispose of treasury shares under articles 2357 and 2357-ter of the Civil Code, subject to the revocation of the unexecuted part of a previous Shareholders' Meeting authorisation dated 09 May 2023. Related and consequent resolutions.
magnihi ciurit odi voluptia venimol ecaesen delesen desciae caborit enimetureped quidel modi ut que sumquam, tem aut ipsum nonem est lit mo qui inihita nobis enturibusam velent quam 4. Report on remuneration policy and payment under Article 123-ter, paragraphs 3-bis and 6 of Legislative Decree no. 58/1998:
estrumetur abo. Ut alis eum as et esti sit ut harum eum aut eaquis is repti cust abore ni omnihic 4.1. First Section: report on remuneration policy. Binding resolution;
ipiciet am dolupid quia digent fugias eostia nossecus, invero od essit,i officeni tem etum laborat 4.2. Second Section: report on remuneration paid. Non-binding resolution.
estrum quodic tet iuntest, quo omnimus reptas eosapitiis dolupta tecullam eum, od modipissunt, 5. Appointment of the Board of Directors. Related and consequent resolutions:
simus. 5.1 Setting the number of Board of Directors members;
- Mo el eum faciden imusam et aut volupta turepedi cus verum adis nobit, qui doluptat. 5.2 Deciding the Board of Directors duration;
Mincium et eiciet pro cus mod ut lacimag natent quam et et est, in nobit eate parchic totatur? 5.3 Appointing the Board of Directors members;
Equam, odit magnistisint alit rati am atus accuptaeped millaborem voluptaquo debisciis nimin 5.4 Appointing the Board of Directors Chairperson;
cuptas nimusdam nonecea non perem int, voloreptatus re voles elenemq uatempe re nis ea 5.5 Establishing the Board of Directors members' remuneration.
archilia sim que autatem andaeprorent aut eumque nullate lab intemporunt elibusant perum volo offic tore occusdae. Sunte dolorib ereribusti dollupta volor arit omnimet utatem. At aut dolorectet 6. Appointment of the Board of Statutory Auditors for the 2024-2026 financial years. Related and consequent resolutions:
haribusa niminullore dolor ad moluptatus utae vendae provit omnimusaesci tendus alicatibus 6.1 Appointing three Statutory Auditors and two Alternate Auditors;
plaboriatiur mi, cus es dolore, cum atectios exeriore conest lacernam rerist, tem et voluptae. 6.2 Appointing the Chairman of the Board of Statutory Auditors;
Elesendi quis nonsequibus alitas eum que core nis accus aperum es evelect atemporendis same 6.3 Establishing the Board of Statutory Auditors members' remuneration.

harchil eum restinis experi consequam alique nonem eosam essit dolles ex erci.

endam rent et videm et qui dis dest mod qui cum sinctur as nis arum quia excestium ime

id moluptatur.

simus.

***

Name Surname Role Company Mus. Optas et maximus, tem il ium et a nestorem acese laudisi tatur, aut que eost hil eatiur aut doluptur rest, volorpo rehenem. Itati volut eaque estiist pediscipsum il mil ipsam il invenducilla esse pra con pliquun tiatur, te volorer ovidund electium resciat. Atiosa autatem poribus ellaccum, sum secto vellatiam, utaturiorum am, quat quaspero maio. Temperum harum qui to conem a abor sunt, odi atureic temo esciaspedis quiassum eum facitas mi, sint, ommoluptatur aut pernatiist fugia quidene modioriatium facepudis ut ommolore solupta erspis quiducilles magnam ium et ad earchit atioremqui arum sunt hit, qui sin nost a dolenimilit lam as volo quid eossincium, ut labo. Ehendicat officet dercill itiatem cum que doluptur It should be noted that under Article 154-ter, paragraph 2, of Legislative Decree no. 58 of 24 February 1998, the Annual Financial Report, including the Consolidated Financial Statements as of 31 December 2023, the Company draft Financial Statements as of 31 December 2023, the Management Report, the certifications under Article 154-bis, paragraph 5 of Legislative Decree 24 February 1998, no. 58 (Consolidated Law on Financial Intermediation - TUF), and the Reports prepared by the Auditing Company and the Board of Statutory Auditors, will be made available to the public today at the Company's registered office, on the Company's website at www.finefoods.it, in the Governance/Meetings section and on the authorised storage system managed by Computershare S.p.A. at . The 31 December 2023 Consolidated Non-Financial Statement prepared under Legislative Decree no. 254 of 30 December 2016, accompanied by the Auditing Company Report, and the Report on Corporate Governance and Ownership Structure under Article 123 bis of the TUF, along with the self-assessment of the Board of Statutory Auditors and self-assessment of the Company's Board of Directors and Board Committees, their size and composition, and directors' independence requirements, will be made available using the same methods and timing. The Financial Statements and summary reports of Fine Foods' subsidiaries under Article 2429, paragraphs 3 and 4, of the Italian Civil Code, will be made public under current regulations' methods and deadlines.

magnihi ciurit odi voluptia venimol ecaesen delesen desciae caborit enimetureped quidel modi ut que sumquam, tem aut ipsum nonem est lit mo qui inihita nobis enturibusam velent quam estrumetur abo. Ut alis eum as et esti sit ut harum eum aut eaquis is repti cust abore ni omnihic Under Art. 154-bis, paragraph 2 of the TUF, the Manager responsible for preparing the corporate financial reports, Pietro Bassani, declared that the accounting information contained in this press release corresponds to the document results, accounting books and records.

ipiciet am dolupid quia digent fugias eostia nossecus, invero od essit,i officeni tem etum laborat estrum quodic tet iuntest, quo omnimus reptas eosapitiis dolupta tecullam eum, od modipissunt, This press release is available on the Fine Foods website www.finefoods.it, in the Investor Relations/Press Releases section.

***

Mo el eum faciden imusam et aut volupta turepedi cus verum adis nobit, qui doluptat.

Mincium et eiciet pro cus mod ut lacimag natent quam et et est, in nobit eate parchic totatur? Equam, odit magnistisint alit rati am atus accuptaeped millaborem voluptaquo debisciis nimin cuptas nimusdam nonecea non perem int, voloreptatus re voles elenemq uatempe re nis ea archilia sim que autatem andaeprorent aut eumque nullate lab intemporunt elibusant perum volo offic tore occusdae. Sunte dolorib ereribusti dollupta volor arit omnimet utatem. At aut dolorectet haribusa niminullore dolor ad moluptatus utae vendae provit omnimusaesci tendus alicatibus plaboriatiur mi, cus es dolore, cum atectios exeriore conest lacernam rerist, tem et voluptae. Elesendi quis nonsequibus alitas eum que core nis accus aperum es evelect atemporendis same nonet volum doluptia quas re ped quaspicipsum dolupta quossitia doluptur saperae volorro ma Fine Foods & Pharmaceuticals N.T.M. S.p.A., listed on Borsa Italiana's Euronext STAR Milan (Ticker: FF) is an Italian independent CDMO (Contract Development and Manufacturing Organisation). It develops and manufactures contract products for the pharmaceutical, nutraceutical and cosmetics industries. Founded in 1984, Fine Foods proved to be a reliable and capable strategic partner for customers in the reference sectors. The company's organisation can provide successful design process and solid, long-term partnerships. The continuous search for excellence is part of the company's business model and includes research and development, innovation, process reliability, product quality, ESG, and sustainable management of the Group's supply chain. Fine Foods is a benefit corporation which relies on certifications and ratings under international standards. These guarantee its sustainability commitment across the business. With €251.8 million revenue in 2023, Fine Foods is a growing and future-oriented company.

conseni quaeser ionserr ovitatempor sitio core quatius prorem quis sinctam, sum quia il eatis ea iducienduci tore anda dolor sequi que acea dia deleniaspero core quis et laccaborenti doloraesecea

harchil eum restinis experi consequam alique nonem eosam essit dolles ex erci.

vel modit idem arum fugiam eos quos reribus molor repudia simagnima endestius solupiet re pro velendanihic testiant.Hillecuptate ne nonetur? Sa sitatquiae. Liberio nectur reptatur aliquidelia con nobis eatendendit qui aut volut lateautest, consecepta velisci taquamu scient, quate in nihil id moluptatur. endam rent et videm et qui dis dest mod qui cum sinctur as nis arum quia excestium ime For further information: Fine Foods & Pharmaceuticals N.T.M. S.p.A. Tel +39 035 4821382 Investor Relations: [email protected] Media Relations: [email protected]

Name Surname Consolidated income statement

Role		Year ended 31 December
Company	Notes	2023	2022

Revenues and income
Mus. Optas et maximus, tem il ium et a nestorem acese laudisi tatur, aut que eost hil Revenues from contracts with customers	2.1	251,811,791	206,852,576
eatiur aut doluptur rest, volorpo rehenem. Itati volut eaque estiist pediscipsum il mil ipsam il Other revenues and income	2.2	1,095,196	1,467,151
invenducilla esse pra con pliquun tiatur, te volorer ovidund electium resciat. Total revenues		252,906,988	208,319,727
Atiosa autatem poribus ellaccum, sum secto vellatiam, utaturiorum am, quat quaspero
maio. Temperum harum qui to conem a abor sunt, odi atureic temo esciaspedis quiassum eum Operating costs
facitas mi, sint, ommoluptatur aut pernatiist fugia quidene modioriatium facepudis ut ommolore Costs for consumption of raw materials, change in inventories of finished goods and work in progress.	2.3	158,188,424	128,033,375
solupta erspis quiducilles magnam ium et ad earchit atioremqui arum sunt hit, qui sin nost a Personnel costs	2.4	44,431,271	38,300,569
dolenimilit lam as volo quid eossincium, ut labo. Ehendicat officet Costs for services	2.5	dercill itiatem cum que doluptur 25,888,270	25,190,520
magnihi ciurit odi voluptia venimol ecaesen delesen desciae caborit enimetureped quidel modi Other operating costs	2.6	2,129,576	1,386,257
ut que sumquam, tem aut ipsum nonem est lit mo qui inihita nobis enturibusam velent quam Amortisation, depreciation, and impairment losses	2.7	21,203,442	16,420,419
estrumetur abo. Ut alis eum as et esti sit ut harum eum aut eaquis is repti cust abore ni omnihic Total operating costs		251,840,983	209,331,140
ipiciet am dolupid quia digent fugias eostia nossecus, invero od essit,i officeni Operating result		1,066,005	tem etum laborat (1,011,413)
estrum quodic tet iuntest, quo omnimus reptas eosapitiis dolupta tecullam eum, od modipissunt,
simus. Changes in fair value of financial assets and liabilities	2.8	1,703,519	(7,733,525)
Mo el eum faciden imusam et aut volupta turepedi cus verum adis nobit, qui doluptat. Loss on financial receivables	2.9	-	(3,266,960)
Mincium et eiciet pro cus mod ut lacimag natent quam et et est, in nobit eate parchic totatur? Financial income	2.10	339,524	59,214
Financial charges Equam, odit magnistisint alit rati am atus accuptaeped millaborem voluptaquo debisciis nimin	2.11	(4,964,248)	(2,246,228)
Income before taxes cuptas nimusdam nonecea non perem int, voloreptatus re voles elenemq uatempe re nis ea		(1,855,199)	(14,198,912)
Income taxes archilia sim que autatem andaeprorent aut eumque nullate lab intemporunt elibusant perum volo	2.12	1,666,899	4,697,768
Profit/(loss) for the financial year offic tore occusdae. Sunte dolorib ereribusti dollupta volor arit omnimet utatem. At aut dolorectet		(3,522,098)	(9,501,145)
Earnings/(loss) per share haribusa niminullore dolor ad moluptatus utae vendae provit omnimusaesci tendus alicatibus
Basic – profit for the year attributable to the Company ordinary  plaboriatiur mi, cus es dolore, cum atectios exeriore conest lacernam rerist, tem et voluptae. shareholders	2.13	(0.14)	(0.37)
Elesendi quis nonsequibus alitas eum que core nis accus aperum es evelect atemporendis same Diluted – profit for the year attributable to the Company ordinary  nonet volum doluptia quas re ped quaspicipsum dolupta quossitia doluptur saperae volorro ma shareholders	2.13	(0.14)	(0.37)

iducienduci tore anda dolor sequi que acea dia deleniaspero core quis et laccaborenti doloraesecea vel modit idem arum fugiam eos quos reribus molor repudia simagnima endestius solupiet re pro Consolidated comprehensive income statement

velendanihic testiant.Hillecuptate ne nonetur? Sa sitatquiae. Liberio nectur reptatur aliquidelia	2023	2022
con nobis eatendendit qui aut volut lateautest, consecepta velisci taquamu scient, quate in nihil Profit /(loss) for the financial year (A)	(3,522,098)	(9,501,145)
id moluptatur.
endam rent et videm et qui dis dest mod qui cum sinctur as nis arum quia excestium ime Components that will not be subsequently reclassified to profit/(loss) for the financial year
eum quo qui quas aut ant ut laborporae. Ut porum et optates mi, ommolor eperit quiassequid Revaluation of net employee benefit liabilities/assets	(33,043)	364,734
Tax effect earunde lluptate ditatur am ut qui as ut laut ditem laborporio molorem saperessi omnissusciis	7,930	(87,536)
dolut magnihil ini corerro es niscia natem reri qui soloratistis velita quam volo quo el et alit Other comprehensive income (B) components harchil eum restinis experi consequam alique nonem eosam essit dolles ex erci.	(25,113)	277,198

Comprehensive profit/(loss) (A+B)	(3,547,211)	(9,223,947)

conseni quaeser ionserr ovitatempor sitio core quatius prorem quis sinctam, sum quia il eatis ea

Name Surname Consolidated statement of financial position

Role Company		As of 31 December	As of 31 December
(amounts in € units)	Notes	2023	2022
Assets
Non-current assets		Mus. Optas et maximus, tem il ium et a nestorem acese laudisi tatur, aut que eost hil
Property, plant and machinery	3.1	106,919,123 eatiur aut doluptur rest, volorpo rehenem. Itati volut eaque estiist pediscipsum il mil ipsam il	104,162,050
Goodwill	3.2	11,507,954	15,907,954
invenducilla esse pra con pliquun tiatur, te volorer ovidund electium resciat. Other intangible fixed assets	3.3	1,634,888	1,780,551
Rights of use	3.4	3,165,607 Atiosa autatem poribus ellaccum, sum secto vellatiam, utaturiorum am, quat quaspero	5,163,111
Other non-current assets	3.5	688,139 maio. Temperum harum qui to conem a abor sunt, odi atureic temo esciaspedis quiassum eum	820,871
Deferred tax assets	3.6	6,234,232 facitas mi, sint, ommoluptatur aut pernatiist fugia quidene modioriatium facepudis ut ommolore	7,312,662
Total non-current assets		130,149,943 solupta erspis quiducilles magnam ium et ad earchit atioremqui arum sunt hit, qui sin nost a	135,147,200
Current assets
dolenimilit lam as volo quid eossincium, ut labo. Ehendicat officet Inventories	3.8	dercill itiatem cum que doluptur 42,459,682	40,422,499
Trade receivables	3.9	38,057,766 magnihi ciurit odi voluptia venimol ecaesen delesen desciae caborit enimetureped quidel modi	39,347,321
Tax receivables	3.10	320,689 ut que sumquam, tem aut ipsum nonem est lit mo qui inihita nobis enturibusam velent quam	2,268,044
Other current assets	3.11	7,740,856 estrumetur abo. Ut alis eum as et esti sit ut harum eum aut eaquis is repti cust abore ni omnihic	5,890,798
Current financial assets ipiciet am dolupid quia digent fugias eostia nossecus, invero od essit,i officeni	3.12	3,832,865	66,512,584 tem etum laborat
Cash and other liquid assets	3.13	19,000,047 estrum quodic tet iuntest, quo omnimus reptas eosapitiis dolupta tecullam eum, od modipissunt,	10,232,262
Total current assets simus.		111,411,905	164,673,509
Total assets		Mo el eum faciden imusam et aut volupta turepedi cus verum adis nobit, qui doluptat. 241,561,848	299,820,709

Shareholders' equity		Mincium et eiciet pro cus mod ut lacimag natent quam et et est, in nobit eate parchic totatur?
Share Capital	4.1	Equam, odit magnistisint alit rati am atus accuptaeped millaborem voluptaquo debisciis nimin 22,770,445	22,770,445
Other reserves	4.1	cuptas nimusdam nonecea non perem int, voloreptatus re voles elenemq uatempe re nis ea 114,167,028	126,461,456
Employee benefit reserve	4.1	archilia sim que autatem andaeprorent aut eumque nullate lab intemporunt elibusant perum volo 181,073	206,186
FTA reserve	4.1	offic tore occusdae. Sunte dolorib ereribusti dollupta volor arit omnimet utatem. At aut dolorectet (6,669,789)	(6,669,789)
Profits carried forward	4.1	22,610 haribusa niminullore dolor ad moluptatus utae vendae provit omnimusaesci tendus alicatibus	22,610
Profit/(loss) for the financial year	4.1	(3,522,098)	(9,501,145)
Total Shareholders' Equity		plaboriatiur mi, cus es dolore, cum atectios exeriore conest lacernam rerist, tem et voluptae. 126,949,268	133,289,763
		Elesendi quis nonsequibus alitas eum que core nis accus aperum es evelect atemporendis same nonet volum doluptia quas re ped quaspicipsum dolupta quossitia doluptur saperae volorro ma
Non-current liabilities
Non-current bank borrowings	4.3	conseni quaeser ionserr ovitatempor sitio core quatius prorem quis sinctam, sum quia il eatis ea 9,734,877	77,573,797
Employee benefits	4.5	2,201,653 iducienduci tore anda dolor sequi que acea dia deleniaspero core quis et laccaborenti doloraesecea	2,419,013
Provision for risks and charges	4.6	2,105 vel modit idem arum fugiam eos quos reribus molor repudia simagnima endestius solupiet re pro	41,105
Provision for deferred taxes	3.7	263,381 velendanihic testiant.Hillecuptate ne nonetur? Sa sitatquiae. Liberio nectur reptatur aliquidelia	240,553
Non-current lease payables	3.4	1,032,604 con nobis eatendendit qui aut volut lateautest, consecepta velisci taquamu scient, quate in nihil	2,222,216
Total non-current liabilities id moluptatur.		13,234,620	82,496,684
Current liabilities		endam rent et videm et qui dis dest mod qui cum sinctur as nis arum quia excestium ime
Bonds	4.2	- eum quo qui quas aut ant ut laborporae. Ut porum et optates mi, ommolor eperit quiassequid	3,323,051
Current bank borrowings	4.4	55,269,592 earunde lluptate ditatur am ut qui as ut laut ditem laborporio molorem saperessi omnissusciis	36,590,346
Trade payables	4.7	32,369,462	33,450,468
Taxes payable	4.8	dolut magnihil ini corerro es niscia natem reri qui soloratistis velita quam volo quo el et alit 575,488	-
Current lease payables	3.3	harchil eum restinis experi consequam alique nonem eosam essit dolles ex erci. 354,377	651,576
Other current liabilities	4.9	12,809,041	10,018,821
Total current liabilities		101,377,960	84,034,262
Total Shareholders' equity and Liabilities		241,561,848	299,820,709

Name Surname Consolidated cash flow statement

Role	Year ended 31 December
Company (amounts in € units)	Notes	2023	2022
PROFIT/(LOSS) FOR THE FINANCIAL YEAR		(3,522,098)	(9,501,145)
Adjustments to reconcile profit after tax with net cash flows:
Depreciation and impairment of property, plant and machinery	2.7	14,756,626	13,267,935
Mus. Optas et maximus, tem il ium et a nestorem acese laudisi tatur, aut que eost hil Amortisation and impairment of intangible fixed assets	2.7	887,277	905,136
Amortisation of rights of use eatiur aut doluptur rest, volorpo rehenem. Itati volut eaque estiist pediscipsum il mil ipsam il	2.7	1,159,538	1,298,706
Other write-downs of fixed assets	2.7	4,400,000	948,642
invenducilla esse pra con pliquun tiatur, te volorer ovidund electium resciat. Impairment of financial receivables	2.9	-	3,266,960
Financial income Atiosa autatem poribus ellaccum, sum secto vellatiam, utaturiorum am, quat quaspero	2.10	(339,524)	(40,528)
Financial charges	2.11	4,916,704	2,179,317
maio. Temperum harum qui to conem a abor sunt, odi atureic temo esciaspedis quiassum eum Changes in fair value of financial assets and liabilities	2.8	(1,703,519)	7,733,525
facitas mi, sint, ommoluptatur aut pernatiist fugia quidene modioriatium facepudis ut ommolore Financial charges on financial liabilities for leases	3.3	47,544	66,911
Income taxes	2.12	557,982	68,715
solupta erspis quiducilles magnam ium et ad earchit atioremqui arum sunt hit, qui sin nost a Gains on the disposal of property, plant and machinery	2.2	(26,247)	(64,906)
dolenimilit lam as volo quid eossincium, ut labo. Ehendicat officet Current assets write-downs	dercill itiatem cum que doluptur 3.8,3.9	762,713	726,198
Net change in severance indemnity and pension funds magnihi ciurit odi voluptia venimol ecaesen delesen desciae caborit enimetureped quidel modi	4.6	(324,435)	(278,278)
Net change in provisions for risks and charges	4.7	(39,000)	39,000
ut que sumquam, tem aut ipsum nonem est lit mo qui inihita nobis enturibusam velent quam Net change in deferred tax assets and liabilities	3.6,3.7	1,108,918	(4,758,703)
estrumetur abo. Ut alis eum as et esti sit ut harum eum aut eaquis is repti cust abore ni omnihic Interest paid	2.10	(4,550,692)	(2,156,964)
Changes in net working capital:
ipiciet am dolupid quia digent fugias eostia nossecus, invero od essit,i officeni (Increase)/decrease in inventories	3.8	tem etum laborat (2,453,558)	(5,944,094)
estrum quodic tet iuntest, quo omnimus reptas eosapitiis dolupta tecullam eum, od modipissunt, (Increase)/decrease in trade receivables	3.9	943,218	(10,064,999)
(Increase)/decrease in other non-financial assets and liabilities simus.		3,037,755	5,078,594
Increase/(decrease) in trade payables	4.7	(1,081,006)	918,351
Mo el eum faciden imusam et aut volupta turepedi cus verum adis nobit, qui doluptat. NET CASH FLOWS FROM OPERATING ACTIVITIES		18,538,195	3,688,374
Mincium et eiciet pro cus mod ut lacimag natent quam et et est, in nobit eate parchic totatur?
Investments: Equam, odit magnistisint alit rati am atus accuptaeped millaborem voluptaquo debisciis nimin
Investments in tangible fixed assets	3.1	(18,126,331)	(15,026,843)
cuptas nimusdam nonecea non perem int, voloreptatus re voles elenemq uatempe re nis ea Disposal of tangible fixed assets	3.1	638,881	209,017
archilia sim que autatem andaeprorent aut eumque nullate lab intemporunt elibusant perum volo Investments in intangible fixed assets	3.3	(741,615)	(957,395)
Net (investments)/disposals in financial assets	3.12	64,116,756	460,635
offic tore occusdae. Sunte dolorib ereribusti dollupta volor arit omnimet utatem. At aut dolorectet NET CASH FLOWS FROM INVESTMENTS		45,887,691	(15,314,586)
haribusa niminullore dolor ad moluptatus utae vendae provit omnimusaesci tendus alicatibus
Financing: plaboriatiur mi, cus es dolore, cum atectios exeriore conest lacernam rerist, tem et voluptae.
New financing	4.3,4.4	2,303,613	72,744,341
Elesendi quis nonsequibus alitas eum que core nis accus aperum es evelect atemporendis same Funding repayment and bonds	4.2,4.3,4.4	(54,519,856)	(62,175,238)
nonet volum doluptia quas re ped quaspicipsum dolupta quossitia doluptur saperae volorro ma Principal payments - lease liabilities	3.3	(648,576)	(1,091,921)
Dividends paid to the parent company's shareholders conseni quaeser ionserr ovitatempor sitio core quatius prorem quis sinctam, sum quia il eatis ea	4.1	(2,452,708)	(3,866,869)
Sale/(purchase) of treasury shares	4.1	(340,575)	(870,796)
iducienduci tore anda dolor sequi que acea dia deleniaspero core quis et laccaborenti doloraesecea CASH FLOWS FROM FINANCING		(55,658,102)	4,739,517
NET CHANGE IN CASH AND CASH EQUIVALENTS vel modit idem arum fugiam eos quos reribus molor repudia simagnima endestius solupiet re pro		8,767,784	(6,886,695)
Cash and short-term deposits as of 1 January		10,232,262	17,118,957
velendanihic testiant.Hillecuptate ne nonetur? Sa sitatquiae. Liberio nectur reptatur aliquidelia Cash and short-term deposits as of 31 December		19,000,047	10,232,262

con nobis eatendendit qui aut volut lateautest, consecepta velisci taquamu scient, quate in nihil

harchil eum restinis experi consequam alique nonem eosam essit dolles ex erci.

endam rent et videm et qui dis dest mod qui cum sinctur as nis arum quia excestium ime

id moluptatur.

Name Surname Consolidated Shareholders' equity changes

Role Company	Notes	Share Capital	Legal reserve	Negative reserve for treasury shares in the portfolio	Merger surplus reserve	Share premium reserve	Extraordinary reserve	Other reserves	FTA reserve	Employee benefit reserve	Profits/losses carried forward	Profit/loss for the financial year	Total Shareholders' equity
Balance as of 31 December 2021 Mus. Optas et maximus, tem il ium et a nestorem acese laudisi tatur, aut que eost hil	4.1	22,770,445 5,000,000		(15,939,707)	29,741,389	86,743,750	19,556,720	7,512,947	(6,669,789)	(71,011)	-	(1,426,751)	147,217,991
Profit/(loss) for the financial year eatiur aut doluptur rest, volorpo rehenem. Itati volut eaque estiist pediscipsum il mil ipsam il												(9,501,145)	(9,501,145)
Other income statement invenducilla esse pra con pliquun tiatur, te volorer ovidund electium resciat. components										277,198			277,198
Atiosa autatem poribus ellaccum, sum secto vellatiam, utaturiorum am, quat quaspero Comprehensive profit/(loss)										277,198		(9,501,145)	(9,223,947)
maio. Temperum harum qui to conem a abor sunt, odi atureic temo esciaspedis quiassum eum Dividends							(3,866,869)						(3,866,869)
facitas mi, sint, ommoluptatur aut pernatiist fugia quidene modioriatium facepudis ut ommolore IRS derivatives provision								33,384					33,384
solupta erspis quiducilles magnam ium et ad earchit atioremqui arum sunt hit, qui sin nost a Stock Grant				3,130,050				(3,130,050)					-
dolenimilit lam as volo quid Purchase of treasury shares		eossincium, ut	labo.	Ehendicat officet (870,796)	dercill	itiatem	cum que	doluptur					(870,796)
magnihi ciurit odi voluptia venimol ecaesen delesen desciae caborit enimetureped quidel modi 2021 profit allocation ut que sumquam, tem aut ipsum nonem est lit mo qui inihita nobis enturibusam velent quam							(1,449,361)				22,610	1,426,751	-
estrumetur abo. Ut alis eum as et esti sit ut harum eum aut eaquis is repti cust abore ni omnihic Balance as of 31 December 2022		22,770,445 5,000,000		(13,680,454)	29,741,389	86,743,750	14,240,490	4,416,281	(6,669,789)	206,186	22,610	(9,501,145)	133,289,763
ipiciet am dolupid quia digent Profit/(loss) for the financial year		fugias eostia	nossecus,	invero	od essit,i	officeni	tem etum	laborat				(3,522,098)	(3,522,098)
estrum quodic tet iuntest, quo omnimus reptas eosapitiis dolupta tecullam eum, od modipissunt, Other income statement components										(25,113)			(25,113)
simus. Comprehensive profit/(loss)	-	-	-	-	-	-	-	-		(25,113)	-	(3,522,098)	(3,547,211)
Mo el eum faciden imusam et aut volupta turepedi cus verum adis nobit, qui doluptat. Dividends Mincium et eiciet pro cus mod ut lacimag natent quam et et est, in nobit eate parchic totatur?							(2,452,708)						(2,452,708)
IRS derivatives provision Equam, odit magnistisint alit rati am atus accuptaeped millaborem voluptaquo debisciis nimin													-
Stock Grant cuptas nimusdam nonecea non perem int, voloreptatus re voles elenemq uatempe re nis ea													-
Purchase of treasury shares archilia sim que autatem andaeprorent aut eumque nullate lab intemporunt elibusant perum volo				(340,575)									(340,575)
offic tore occusdae. Sunte 2022 profit allocation	dolorib	ereribusti	dollupta	volor arit	omnimet	utatem.	At aut (9,501,145)	dolorectet				9,501,145	-
haribusa niminullore dolor ad moluptatus utae vendae provit omnimusaesci tendus alicatibus Balance as of 31 December 2023		22,770,445 5,000,000		(14,021,029)		29,741,389 86,743,750	2,286,638	4,416,281	(6,669,789)	181,073	22,610	(3,522,098)	126,949,268

endam rent et videm et qui dis dest mod qui cum sinctur as nis arum quia excestium ime

Elesendi quis nonsequibus alitas eum que core nis accus aperum es evelect atemporendis same

harchil eum restinis experi consequam alique nonem eosam essit dolles ex erci.

CF / P.IVA IT 09320600969 CAP. SOC. € 22.770.445,02 FINEFOODS.IT

AI Terminal

Fine Foods & Pharmaceuticals Ntm

4495_rns_2024-03-29_62e466ac-8602-42c9-9348-383344faaea1.pdf

maio. Temperum harum qui to conem a abor sunt, odi atureic temo esciaspedis quiassum eum facitas mi, sint, ommoluptatur aut pernatiist fugia quidene modioriatium facepudis ut ommolore Highlights

Equam, odit magnistisint alit rati am atus accuptaeped millaborem voluptaquo debisciis nimin cuptas nimusdam nonecea non perem int, voloreptatus re voles elenemq uatempe re nis ea EVENTS FOLLOWING THE END OF THE PERIOD

offic tore occusdae. Sunte dolorib ereribusti dollupta volor arit omnimet utatem. At aut dolorectet haribusa niminullore dolor ad moluptatus utae vendae provit omnimusaesci tendus alicatibus BUSINESS OUTLOOK

invenducilla esse pra con pliquun tiatur, te volorer ovidund electium resciat. Atiosa autatem poribus ellaccum, sum secto vellatiam, utaturiorum am, quat quaspero PROPOSED DIVIDEND DISTRIBUTION

simus. Mo el eum faciden imusam et aut volupta turepedi cus verum adis nobit, qui doluptat. CONSOLIDATED NON-FINANCIAL STATEMENT UNDER LEGISLATIVE DECREE 254/2016

Name Surname SHAREHOLDERS' MEETING CONVOCATION

Name Surname Consolidated income statement

iducienduci tore anda dolor sequi que acea dia deleniaspero core quis et laccaborenti doloraesecea vel modit idem arum fugiam eos quos reribus molor repudia simagnima endestius solupiet re pro Consolidated comprehensive income statement

Name Surname Consolidated statement of financial position

Name Surname Consolidated cash flow statement

Name Surname Consolidated Shareholders' equity changes

More from Fine Foods & Pharmaceuticals Ntm

Talk to a Data Expert